I am a medical oncologist who cares for people with lymphoma. I am also a researcher who studies the disease. I am part of a team of world-class lymphoma experts who have more than 100 years of combined experience and a shared goal of providing the most effective, personalized care for people with this disease.
At MSK, we treat lymphoma with a variety of techniques, including chemotherapy, immunotherapy, targeted therapy, radiotherapy, and stem cell transplantation. Depending on each patient’s unique situation, some or all of these treatment methods may be used. We work together as a team to create a comprehensive care plan, starting with our scientific knowledge as the foundation.
My research focuses on lymphoma genetics, mechanism-based therapies for targeted therapy, and the application of chimeric antigen receptor T cells — called CAR T cells — in the treatment of lymphoma. I am currently involved in a number of clinical trials that are looking at immunotherapy, new combinations of drugs, and biomarker-based targeted therapies. Ultimately, my task as a clinical researcher is to understand the journey of each patient and to work to develop therapies that minimize the footprint lymphoma leaves on their lives.
I realize the devastation that a cancer diagnosis can cause in someone’s life, and the lives of their loved ones, and that treatment can be emotionally and logistically difficult. When people come to MSK, I hope they feel they have gained new advocates who will be with them throughout their entire journey.
- Clinical Expertise: Hodgkin Lymphoma; Non-Hodgkin Lymphoma
- Languages Spoken: English
- Education: MD, University of Massachusetts Medical School
- Residencies: Internal Medicine - Mount Sinai Hospital/Mount Sinai School of Medicine
- Fellowships: Hematology/Oncology - Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Oncology
Batlevi C, Horwitz SM, Moskowitz CH, Zelenetz AD, Palomba L, et al. “Targeted Genomic Sequencing Prospectively Identifies Clinically Relevant Genetic Alterations Across Lymphoma Subtypes”; 13th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2015. Oral Abstract.1.
Batlevi CW, Kasamon Y, Bociek RG, Lee P, Gore L, Copeland A, Sorensen R, Ordentlich P, Cruickshank S, Kunkel L, Buglio D, Hernandez-Ilizaliturri F, Younes A. “ENGAGE- 501: Phase 2 Study of Entinostat (SNDX-275) in Relapsed and Refractory Hodgkin Lymphoma.” Haematologica. Epub 2016/05/05. pii: haematol.2016.142406. PMID: 27151994.
Batlevi CL, Younes A. Novel therapy for Hodgkin lymphoma. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2013;2013:394-9. Epub 2013/12/10. doi: 10.1182/asheducation-2013.1.394. PubMed PMID: 24319210.
Batlevi CL, Younes A. Diffuse large B-cell lymphoma: changing treatment paradigms. Oncology (Williston Park, NY). 2014;28(4):339-41. Epub 2014/05/21. PubMed PMID: 24839810.
Batlevi CL, Anas Y. “Hodgkin lymphoma microenvironment: old and new therapeutic targets”, Lymphoma, Volume 2, Future Medicine, 2014; 36-55. Ebook ISBN: 978-1-78084-582-1
Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel immunotherapies in lymphoid malignancies. Nature reviews Clinical oncology. 2016;13(1):25-40. Epub 2015/11/04. doi: 10.1038/nrclinonc.2015.187. PubMed PMID: 26525683.
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more